Ardelyx Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities
Company achieved significant commercial progress in 2023
IBSRELA® now expected to generate greater than $1.0 billion in annual U.S. net product sales revenue at peak
Related news for (ARDX)
- Today’s Top Performers: MoBot’s Market Review 08/05/25 09:00 AM
- Ardelyx Reports Second Quarter 2025 Financial Results and Provides Business Update
- Ardelyx Announces Changes to the Executive Leadership Team
- MoBot’s Stock Market Highlights – 08/04/25 04:00 PM
- 24/7 Market News Snapshot 04 August, 2025 – Ardelyx, Inc. (NASDAQ:ARDX)